SOLANA BEACH, Calif. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock,
SOLANA BEACH, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached an agreement to work in partnership with Spaulding Clinical Research
SOLANA BEACH, Calif. , June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti ® (metoclopramide) nasal spray is now listed in the
SOLANA BEACH, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the underwriter of its previously announced public offering of approximately 2.4 million shares of
SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an
SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
SOLANA BEACH, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co.
Healthcare practitioner survey indicates physicians’ awareness and intent to prescribe newly-launched product SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
